Clinical trial recruitment and retention remain challenges in the quest to bring innovative therapies to all patients in need. In oncology, therapies continue to evolve, yet researchers are frequently faced with low trial participation, particularly among minority groups. Oncology Practice Management (OPM) is dedicated to providing comprehensive information aimed at eliminating health disparities and improving access to therapies for people from all populations, including racial and ethnic minorities; people with limited access to healthcare due to lack of financial resources; and people living in rural communities.
This new feature in OPM aims to provide ongoing lists of US-based phase 2 or 3 clinical trials that are actively recruiting. This issue is focused on sarcoma, the July cancer awareness month. Healthcare practitioners may use this listing in discussions with their patients to encourage enrollment. As the National Comprehensive Cancer Network has stated, “The best management of any cancer patient is in a clinical trial.”
These clinical trial listings can be found at www.ClinicalTrials.gov.
- Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT05109494
- Sponsor: University of Wisconsin, Madison
- Pomalidomide Treatment in Patients With Kaposi Sarcoma
- ClinicalTrials.gov identifier: NCT04577755
- Sponsor: National Cancer Institute
- Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT04506008
- Sponsor: Vanderbilt-Ingram Cancer Center
- sEphB4-HSA in Treating Patients With Kaposi Sarcoma
- ClinicalTrials.gov identifier: NCT02799485
- Sponsor: AIDS Malignancy Consortium
- Collaborators
- National Cancer Institute
- Vasgene Therapeutics, Inc
- The Emmes Company, LLC
- University of Arkansas
- Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
- ClinicalTrials.gov identifier: NCT04204941
- Sponsor: Epizyme, Inc
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
- ClinicalTrials.gov identifier: NCT04028063
- Sponsor: University of Colorado, Denver
- Collaborator: Agenus Inc
- Trial of Ixazomib for Kaposi Sarcoma
- ClinicalTrials.gov identifier: NCT04305691
- Sponsor: AIDS Malignancy Consortium
- Collaborator: National Cancer Institute
- Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study
- ClinicalTrials.gov identifier: NCT05333458
- Sponsor: National Cancer Institute
- Evaluating the Impact of Limited Compared With Intense Post-Operative Surveillance on Patient-Reported Outcomes in Patients With Stage II-III Soft Tissue Sarcoma of the Trunk and Extremities
- ClinicalTrials.gov identifier: NCT04751409
- Sponsor: MD Anderson Cancer Center
- Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma
- ClinicalTrials.gov identifier: NCT05726383
- Sponsor: Hackensack Meridian Health
- Collaborators
- MD Anderson Cancer Center
- Iscador AG, Arlesheim, Switzerland
- Tackle Kids Cancer
- Susan Zabransky Hughes Foundation
- CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
- ClinicalTrials.gov identifier: NCT05440786
- Sponsor: Eli Lilly and Company
- Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
- ClinicalTrials.gov identifier: NCT04040205
- Sponsor: Medical College of Wisconsin
